• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WNS to acquire Value Edge Research Services for $17.5M

WNS to acquire Value Edge Research Services for $17.5M

March 14, 2016
CenterWatch Staff

WNS, a provider of global business process management services, has entered into a definitive agreement to acquire Value Edge Research Services, a provider of commercial research and analytics services to clients in the pharma/biopharma industry.

Value Edge provides consulting grade marketing and data analytics to a blue-chip roster of globally leading biopharma companies. Value Edge has created a cloud-based advanced technology platform designed to provide clients with competitive intelligence to drive strategic decision-making. Core company offerings include CI, opportunity assessment, forecasting, reporting & dash-boarding, modeling, business intelligence tool building and data analysis. The company also provides services in the areas of pricing analytics, patient data analysis, key account management, sales force effectiveness and social media monitoring.

 “The acquisition of Value Edge deepens our domain and specialized analytical capabilities in the growing pharma market, and provides WNS with a technology asset which is leverageable across clients and industries,” said Keshav Murugesh, WNS’ chief executive officer. “We are thrilled to welcome Value Edge’s talented industry experts to the WNS family, and look forward to jointly creating new opportunities and true business value for our clients.”

“Value Edge is excited to partner with WNS, and the combination of our firms’ respective capabilities will enable us to help clients in the pharma/biopharma industry improve their competitive positioning,” said Rohit Anand, Value Edge’s founder and managing director. “We believe WNS’ global size and strength will allow us to tap new areas of demand, drive deeper relationships and expand our offerings.”

The acquisition of Value Edge is subject to Reserve Bank of India approval and other customary closing conditions, and is expected to close in the first quarter of fiscal 2017. Cash consideration for the transaction is $17.5 million plus adjustments for cash and working capital. WNS intends to fund the consideration with cash on hand. Based on Value Edge’s existing book of business, the acquisition is expected to contribute approximately $5 million in revenue for WNS in fiscal 2017. The acquisition is also expected to be accretive to earnings in fiscal 2017.

Value Edge currently employs over 100 people in India, the U.S. and Europe.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing